Circulating autoantibodies to alpha-enolase (ENO1) and far upstream element-binding protein 1 (FUBP1) are negative prognostic factors for pancreatic cancer patient survival.
Alpha-enolase
Circulating autoantibodies
Far upstream element-binding protein 1
Pancreatic ductal adenocarcinoma
Journal
Clinical and experimental medicine
ISSN: 1591-9528
Titre abrégé: Clin Exp Med
Pays: Italy
ID NLM: 100973405
Informations de publication
Date de publication:
01 Nov 2023
01 Nov 2023
Historique:
received:
10
07
2023
accepted:
24
10
2023
medline:
1
11
2023
pubmed:
1
11
2023
entrez:
1
11
2023
Statut:
aheadofprint
Résumé
Pancreatic ductal adenocarcinoma (PDA) has a dismal prognosis due to a lack of early diagnostic markers and effective therapy. In PDA patients, the glycolytic enzyme and plasminogen receptor alpha-enolase (ENO1) and the transcription factor far upstream element-binding protein 1 (FUBP1) are upregulated and elicit the production of autoantibodies (aAb) that discriminate healthy subjects from PDA patients, with the latter mostly directed to post-translational phosphorylated isoforms. Here, the correlation of prognosis with circulating ENO1 and FUBP1aAb, and their protein tissue expression was analyzed in PDA patients. Circulating ENO1 and FUBP1 aAb was analyzed in two cohorts of PDA patients by ELISA (n = 470), while tissues expression was observed by immunohistochemistry (n = 45). Overall survival (OS) was estimated using the Kaplan-Meier method, while the Cox model was used to estimate the hazard ratios (HR) adjusted for the main prognostic factors. Logistic models were applied to assess associations between death and its risk indicators. All statistical analyses were performed with Stata version 15. Unlike ENO1 aAb, there was a significant correlation between FUBP1 aAb and FUBP1 expression in tumors (p = 0.0268). In addition, we found that high ENO1 (p = 0.016) and intermediate FUBP1 aAb levels (p = 0.013) were unfavorable prognostic factors. Notably, it was found that high anti-FUBP1 aAb level is a good prognostic marker for tail-body PDA (p = 0.016). Our results suggest that different levels of circulating aAb to ENO1 and FUBP1 predict a poor outcome in PDA patients and can be used to improve therapeutic strategies.
Identifiants
pubmed: 37910256
doi: 10.1007/s10238-023-01236-5
pii: 10.1007/s10238-023-01236-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Grant for Internalization
ID : CURC_GFI_22_01_F
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : IG no. 27020
Organisme : Bando CRT Città della Salute e della Scienza di Torino
ID : no. 2019.1887
Organisme : European Union - Next Generation EU - NRRP M6C2 - Investment 2.1 Enhancement and strengthening of biomedical research in the NHS
ID : PNRR-POC-2022-12375658
Organisme : Fondazione Ricerca Molinette Onlus
ID : CD38 and Associazione Ursula e Giorgio Cytron
Informations de copyright
© 2023. The Author(s).
Références
Sivapalan L, Kocher HM, Ross-Adams H, et al. The molecular landscape of pancreatic ductal adenocarcinoma. Pancreatology. 2022;22:925–36.
pubmed: 35927150
doi: 10.1016/j.pan.2022.07.010
Malafa PM. Defining borderline resectable pancreatic cancer: emerging consensus for an old challenge. J Natl Compr Cancer Netw. 2015;13:501–4.
doi: 10.6004/jnccn.2015.0068
Pereira SP, Oldfield L, Ney A, et al. Early detection of pancreatic cancer. Lancet Gastroenterol Hepatol. 2020;5:698–710.
pubmed: 32135127
pmcid: 7380506
doi: 10.1016/S2468-1253(19)30416-9
Wang Z, Li Y, Ahmad A, et al. Pancreatic cancer: understanding and overcoming chemoresistance. Nat Rev Gastroenterol Hepatol. 2011;8:27–33.
pubmed: 21102532
doi: 10.1038/nrgastro.2010.188
Zhang X, Li J, Wang Y, et al. A diagnostic model with igm autoantibodies and carcinoembryonic antigen for early detection of lung adenocarcinoma. Front Immunol. 2022;12:728853.
pubmed: 35140701
pmcid: 8818794
doi: 10.3389/fimmu.2021.728853
Patel AJ, Tan TM, Richter AG, et al. A highly predictive autoantibody-based biomarker panel for prognosis in early-stage NSCLC with potential therapeutic implications. Br J Cancer. 2022;126:238–46.
pubmed: 34728792
doi: 10.1038/s41416-021-01572-x
Almaguel FA, Sanchez TW, Ortiz-Hernandez GL, et al. Alpha-enolase: emerging tumor-associated antigen, cancer biomarker, and oncotherapeutic target. Front Genet. 2021;11:614726.
pubmed: 33584813
pmcid: 7876367
doi: 10.3389/fgene.2020.614726
Rastogi A, Ali A, Tan SH, et al. Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC. AMACR HERV-K Gag G Cancer. 2016;7:394–413.
Tomaino B, Cappello P, Capello M, et al. Autoantibody signature in human ductal pancreatic adenocarcinoma. J Prot Res. 2007;6:4025–31.
doi: 10.1021/pr070281a
Tomaino B, Cappello P, Capello M, et al. Circulating autoantibodies to phosphorylated α-enolase are a hallmark of pancreatic cancer. J Prot Res. 2011;10:105–12.
doi: 10.1021/pr100213b
Mandili G, Curcio C, Bulfamante S, et al. In pancreatic cancer, chemotherapy increases antitumor responses to tumor-associated antigens and potentiates DNA vaccination. J Immunother Cancer. 2020;8:e001071.
pubmed: 33115943
pmcid: 7594541
doi: 10.1136/jitc-2020-001071
Duan J, Bao X, Ma X, et al. Upregulation of far upstream element-binding protein 1 (fubp1) promotes tumor proliferation and tumorigenesis of clear cell renal cell carcinoma. PLoS ONE. 2017;12:e0169852.
pubmed: 28076379
pmcid: 5226774
doi: 10.1371/journal.pone.0169852
Chen Y, Liu J, Geng N, et al. Upregulation of far upstream element-binding protein 1 (fubp1) promotes tumor proliferation and unfavorable prognosis in tongue squamous cell carcinoma. Int J Biol Markers. 2020;35:56–65.
pubmed: 32339054
doi: 10.1177/1724600820912252
Huang Y, Xu X, Ji L, et al. Expression of far upstream element binding protein 1 in B cell non Hodgkin lymphoma is correlated with tumor growth and cell adhesion mediated drug resistance. Mol Med Rep. 2016;14:3759–68.
pubmed: 27599538
doi: 10.3892/mmr.2016.5718
Wang S, Wang Y, Li S, et al. Far upstream element -binding protein 1 (FUBP1) participates in the malignant process and glycolysis of colon cancer cells by combining with c-Myc. Bioengineered. 2022;13:12115–26.
pubmed: 35546072
pmcid: 9276009
doi: 10.1080/21655979.2022.2073115
Marquina G, Manzano A, Casado A. Targeted agents in cervical cancer: beyond bevacizumab. Curr Oncol Rep. 2018;20:40.
pubmed: 29611060
doi: 10.1007/s11912-018-0680-3
Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and ras mutations in colorectal cancer. N Engl J Med. 2013;369:1023–34.
pubmed: 24024839
doi: 10.1056/NEJMoa1305275
Debaize L, Troadec MB. The master regulator fubp1: its emerging role in normal cell function and malignant development. Cell Mol Life Sci. 2019;76:259–81.
pubmed: 30343319
doi: 10.1007/s00018-018-2933-6
Zhang XX, Chen H, Li HY, et al. Long non-coding RNA small nucleolar RNA host gene 6 aggravates pancreatic cancer through upregulation of far upstream element binding protein 1 by sponging microrna-26a-5p. Chin Med J. 2020;133:1211–20.
pubmed: 32433053
pmcid: 7249703
doi: 10.1097/CM9.0000000000000758
Jang M, Park BC, Kang S, et al. Far upstream element-binding protein-1, a novel caspase substrate, acts as a cross-talker between apoptosis and the c-myc oncogene. Oncogene. 2009;28:1529–36.
pubmed: 19219071
doi: 10.1038/onc.2009.11
Avigan MI, Strober B, Levens D. A far upstream element stimulates c-myc expression in undifferentiated leukemia cells. J Biol Chem. 1990;265:18538–45.
pubmed: 2211718
doi: 10.1016/S0021-9258(17)44785-5
Duncan R, Bazar L, Michelotti G, et al. A sequence-specific, single-strand binding protein activates the far upstream element of c-myc and defines a new DNA- binding motif. Genes Dev. 1994;8:465–80.
pubmed: 8125259
doi: 10.1101/gad.8.4.465
Chan AK-Y, Pang JC-S, Chung NY-F, et al. Loss of CIC and FUBP1 expressions are potential markers of shorter time to recurrence in oligodendroglial tumors. Mod Pathol. 2014;27:332–42.
pubmed: 24030748
doi: 10.1038/modpathol.2013.165
Kang M, Kim HJ, Kim T-J, et al. Multiple functions of Fubp1 in cell cycle progression and cell survival. Cells. 2020;9:1347.
pubmed: 32481602
pmcid: 7349734
doi: 10.3390/cells9061347
Zhao Y, Hu X, Liu Y, et al. ROS signaling under metabolic stress: cross-talk between AMPK and AKT pathway. Mol Cancer. 2017;16:79.
pubmed: 28407774
pmcid: 5390360
doi: 10.1186/s12943-017-0648-1
Yokoyama C, Sueyoshi Y, Ema M, et al. Induction of oxidative stress by anticancer drugs in the presence and absence of cells. Oncol Lett. 2017;14:6066–70.
pubmed: 29113247
pmcid: 5661396
Liu J, Chung HJ, Vogt M, et al. JTV1 co-activates FBP to induce USP29 transcription and stabilize p53 in response to oxidative stress. EMBO J. 2011;30:846–58.
pubmed: 21285945
pmcid: 3049210
doi: 10.1038/emboj.2011.11
Fan P, Ma J, Jin X. Far upstream element-binding protein 1 is up-regulated in pancreatic cancer and modulates immune response by increasing programmed death ligand 1. Biochem Biophys Res Comun. 2018;505:830–6.
doi: 10.1016/j.bbrc.2018.10.009
Zhang Y, Chen J, Zhou N, et al. FUBP1 mediates the growth and metastasis through TGFβ/Smad signaling in pancreatic adenocarcinoma. Int J Mol Med. 2021;47:66.
pubmed: 33649780
pmcid: 7952245
doi: 10.3892/ijmm.2021.4899
Xu W, Yang W, Wu C, et al. Enolase 1 correlated with cancer progression and immune-infiltrating in multiple cancer types: a pan-cancer analysis. Front Oncol. 2021;10:593706.
pubmed: 33643901
pmcid: 7902799
doi: 10.3389/fonc.2020.593706
Hoang AT, Vizio B, Chiusa L, et al. Impact of tissue enolase 1 protein overexpression in esophageal cancer progression. Int J Med Sci. 2021;18:1406–14.
pubmed: 33628097
pmcid: 7893569
doi: 10.7150/ijms.52688
Harrell FE. Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. New York: Springer; 2001.
doi: 10.1007/978-1-4757-3462-1
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods. 2001;25:402–8.
pubmed: 11846609
doi: 10.1006/meth.2001.1262
Yin H, Wang L, Liu H-L. ENO1 overexpression in pancreatic cancer patients and its clinical and diagnostic significance. Gastroenterol Res Pract. 2018;2018:3842198.
pubmed: 29483925
pmcid: 5816842
doi: 10.1155/2018/3842198
Pupa SM, Invernizzi AM, Forti S, et al. Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination. Gene Ther. 2001;8:75–9.
pubmed: 11402305
doi: 10.1038/sj.gt.3301360
Lu Y, Wei YQ, Tian L, et al. Immunogene therapy of tumors with vaccine based on xenogeneic epidermal growth factor receptor. J Immunol. 2003;170:3162–70.
pubmed: 12626574
doi: 10.4049/jimmunol.170.6.3162
Ghaneh P, Palmer D, Cicconi S, et al. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8:157–68.
pubmed: 36521500
doi: 10.1016/S2468-1253(22)00348-X
Sugawara T, Rodriguez Franco S, Sherman S, et al. Association of adjuvant chemotherapy in patients with resected pancreatic adenocarcinoma after multiagent neoadjuvant chemotherapy. JAMA Oncol. 2023;9:316–23.
pubmed: 36480190
doi: 10.1001/jamaoncol.2022.5808
Maruta A, Iwashita T, Yoshida K, et al. Evaluation of preoperative diagnostic methods for resectable pancreatic cancer: a diagnostic capability and impact on the prognosis of endoscopic ultrasound-guided fine needle aspiration. BMC Gastroenterol. 2021;21:382.
pubmed: 34663214
pmcid: 8524976
doi: 10.1186/s12876-021-01955-7
Takagi K, Umeda Y, Yoshida R, et al. Role of surgery for pancreatic ductal adenocarcinoma in the era of multidisciplinary treatment. J Clin Med. 2023;12:465.
pubmed: 36675394
pmcid: 9867067
doi: 10.3390/jcm12020465
Springfeld C, Ferrone CR, Katz MHG, et al. Neoadjuvant therapy for pancreatic cancer. Nat Rev Clin Oncol. 2023;20:318–37.
pubmed: 36932224
doi: 10.1038/s41571-023-00746-1
Ying X, Han S-X, He C-C, et al. Autoantibodies against glucose-regulated protein 78 as serological biomarkers in metastatic and recurrent hepatocellular carcinoma. Oncotarget. 2017;8:24828–39.
pubmed: 28186997
pmcid: 5421892
doi: 10.18632/oncotarget.15192
Khageh Hosseini S, Kolterer S, Steiner M, et al. Camptothecin and its analog SN-38, the active metabolite of irinotecan, inhibit binding of the transcriptional regulator and oncoprotein FUBP1 to its DNA target sequence FUSE. Biochem Pharmacol. 2017;146:53–62.
pubmed: 29031818
doi: 10.1016/j.bcp.2017.10.003
Niccolai E, Cappello P, Taddei A, et al. Peripheral ENO1-specific T cells mirror the intratumoral immune response and their presence is a potential prognostic factor for pancreatic adenocarcinoma. Int J Oncol. 2016;49:393–401.
pubmed: 27210467
doi: 10.3892/ijo.2016.3524
Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22:329–60.
pubmed: 15032581
doi: 10.1146/annurev.immunol.22.012703.104803
Cappello P, Rolla S, Chiarle R, et al. Vaccination with ENO1 DNA prolongs survival of genetically engineered mice with pancreatic cancer. Gastroenterology. 2013;144:1098–106.
pubmed: 23333712
doi: 10.1053/j.gastro.2013.01.020